Business Wire

HERMAN-MILLER

Share
Herman Miller Continues Expansion of Pioneering Use of Ocean-Bound Plastic With Updated Sayl Chair

Herman Miller is continuing to increase the use of ocean-bound plastic within the modern furniture maker’s portfolio. The Sayl Chair, designed by esteemed Swiss Designer Yves Béhar will now include up to 1.36 kg (3 pounds) of mismanaged plastic waste found near waterways. This change builds upon the momentum created by the introduction of ocean-plastic in the iconic Aeron Chair in 2021 and will divert 95 metric tons*, the equivalent of approximately 9.6 million plastic water bottles, from the ocean annually.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005101/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Herman Miller Continues Expansion of Pioneering Use of Ocean-Bound Plastic With Updated Sayl Chair (Photo: Business Wire)

As part of the MillerKnoll collective, today’s announcement highlights Herman Miller’s ongoing commitment to sustainability, and long-term goal to increase recycled content to at least 50 percent, including the use of ocean-bound plastic, across all material the Company uses by 2030.

Sayl joins an impressive roster of Herman Miller products now being made with ocean-bound plastic. Between Aeron, Sayl, and other product lines including OE1 and Revenio textiles, the Company estimates that 234 metric tons of ocean-bound plastic, the equivalent of 23 million water bottles, will be diverted from the ocean annually.

“True innovation isn’t always about making new products,” says Gabe Wing, Director of Sustainability at MillerKnoll. “Oftentimes it can be looking for ways to use new research, perspectives, and resources to improve what already exists. Our team is incredibly excited to continue to improve and introduce products that promote responsible use of Earth’s resources.”

Since its introduction in 2010, the Sayl chair has been a leader in responsible design. Inspired by the Golden Gate Bridge, the eco-dematerialized design of Sayl was specifically created to use less material in inventive ways while providing ergonomic support and comfort. Additionally, the chair is 92% recyclable at the end of life.

Yves Béhar, the designer of Sayl and founder of fuseproject, commented on the announcement: “Charles Eames once said ‘Design is never done.’ That is true for the Sayl chair as improvements continue to be made years and years after launch. It was designed from the start as a light, simple, and lower carbon footprint chair in the full-featured task chairs category. And now, years after its launch I’m excited to see Sayl manufactured in recycled plastic diverted from rivers and oceans as the next step in bettering the design. At fuseproject, that has always been a focus and passion, and will continue to be central to our work.”

All colours of the Sayl chair will include ocean-bound plastic, which will grow to include the special edition versions created for Herman Miller Gaming in the future. Depending on the color chosen, each Sayl will have between .907kg (2 pounds) and 1.36kg (3 pounds) of ocean-bound plastic incorporated, with the Black version of Sayl having the highest. Sayl with ocean-bound plastic is available in Europe now and will be available in other areas of the globe later in 2023.

Herman Miller also announced that all colours of the Aeron are now available with ocean-bound plastic starting in November. The Onyx, Graphite, Mineral, and Carbon colours contain up to 1.13 kg (2.5 pounds) of ocean-bound plastic per chair.

To learn more about the specific environmental information for each variation of the Sayl or Aeron Chairs and to see how purchasing these items can contribute to green building standards including LEED, please visit https://millerknoll.ecomedes.com/.

About Herman Miller

Since 1905, Herman Miller has been guided by a commitment to problem-solving designs that inspire the best in people. Along the way, Herman Miller has forged critical relationships with the most visionary designers of the day, from midcentury greats like George Nelson, the Eames Office, and Isamu Noguchi, to research-oriented visionaries like Robert Propst and Bill Stumpf — and with today’s groundbreaking studios like Industrial Facility and Studio 7.5. From the birth of ergonomic furniture to manufacturing some of the twentieth century’s most iconic pieces, Herman Miller has spent the last century pioneering original, timeless design that makes an enduring impact, while building a lasting legacy of design, innovation and social good. Herman Miller is a part of MillerKnoll, a collective of dynamic brands that comes together to design the world we live in.

*Based on current selling forecasts.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005101/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 14:00:00 CET | Press release

Prospective, randomized controlled trial compares novel femtosecond laser procedure to selective laser trabeculoplasty (SLT), advancing path to US commercialization ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous e

Winchester Interconnect Launches LiteSPEed™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 14:00:00 CET | Press release

Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has

Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 14:00:00 CET | Press release

Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa

Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 14:00:00 CET | Press release

News summary: Critical infrastructure, defense and governments need quantum-safe encryption at the edge to neutralize ‘harvest-now, decrypt-later’ risks FSP 150-XG118Pro (CSH) delivers quantum-safe encryption via software update, enabling seamless upgrades with no hardware changes BSI approval confirms the device’s compliance for government and defense use Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infra

Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing3.12.2025 14:00:00 CET | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye